1. Cholecalciferol decreases inflammation and improves vitamin D regulatory enzymes in lymphocytes in the uremic environment: A randomized controlled pilot trial
- Author
-
Miguel Cendoroglo, Lilian Cuppari, Caren Cristina Grabulosa, Marcelo C. Batista, Maria Aparecida Dalboni, Beata Marie Quinto Redublo, Danilo Takashi Aoike, José Tarcísio Giffoni de Carvalho, Rosa M.A. Moysés, and Marion Schneider
- Subjects
0301 basic medicine ,25-Hydroxyvitamin D3 1-alpha-hydroxylase ,030232 urology & nephrology ,lcsh:Medicine ,Organic chemistry ,Vitamin D3 24-Hydroxylase ,Pilot Projects ,Pathology and Laboratory Medicine ,Calcitriol receptor ,Biochemistry ,Immune Receptors ,Placebos ,chemistry.chemical_compound ,White Blood Cells ,0302 clinical medicine ,Animal Cells ,polycyclic compounds ,Medicine and Health Sciences ,Medicine ,Lymphocytes ,Vitamin D ,lcsh:Science ,Enzyme Chemistry ,Immune Response ,Toll-like Receptors ,Cholecalciferol ,Multidisciplinary ,Immune System Proteins ,T Cells ,Vitamins ,Gene Pool ,Physical sciences ,Chemistry ,Nephrology ,Cytokines ,lipids (amino acids, peptides, and proteins) ,Inflammation Mediators ,Cellular Types ,Research Article ,Signal Transduction ,medicine.medical_specialty ,Immune Cells ,Immunology ,Enzyme Regulation ,03 medical and health sciences ,Chemical compounds ,Immune system ,Signs and Symptoms ,CYP24A1 ,Double-Blind Method ,Diagnostic Medicine ,Internal medicine ,Organic compounds ,Medical Dialysis ,Vitamin D and neurology ,Genetics ,Humans ,Uremia ,25-Hydroxyvitamin D3 1-alpha-Hydroxylase ,Inflammation ,Evolutionary Biology ,Blood Cells ,Population Biology ,business.industry ,lcsh:R ,Biology and Life Sciences ,Proteins ,Cell Biology ,medicine.disease ,030104 developmental biology ,Endocrinology ,chemistry ,Case-Control Studies ,Enzymology ,Receptors, Calcitriol ,lcsh:Q ,business ,Population Genetics - Abstract
It has been reported that vitamin D regulates the immune system. However, whether vitamin D repletion modulates inflammatory responses in lymphocytes from dialysis patients is unclear. In the clinical trial, thirty-two (32) dialysis patients with 25 vitamin D ≤ 20ng/mL were randomized to receive either supplementation of cholecalciferol 100,000 UI/week/3 months (16 patients) or placebo (16 patients). In the in vitro study, B and T lymphocytes from 12 healthy volunteers (HV) were incubated with or without uremic serum in the presence or absence of 25 or 1,25 vitamin D. We evaluated the intracellular expression of IL-6, IFN-γ TLR7, TLR9, VDR, CYP27b1 and CYP24a1 by flow cytometry. We observed a reduction in the expression of TLR7, TLR9, INF-γ and CYP24a1 and an increase in VDR and CYP27b1 expression in patients which were supplemented with cholecalciferol, whereas no differences were found in the placebo group. Uremic serum increased the intracellular expression of IL-6, IFN-γ, TLR7, TLR9, VDR, CYP27b1 and CYP24a1. Treatment with 25 or 1,25 vitamin D decreased IL-6 and TLR9. CYP24a1 silencing plus treatment with 25 and/or 1,25 vitamin D had an additional reduction effect on IL-6, IFN-γ, TLR7 and TLR9 expression. This is the first study showing that cholecalciferol repletion has an anti-inflammatory effect and improves vitamin D intracellular regulatory enzymes on lymphocytes from dialysis patients.
- Published
- 2016